Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc begins tender offer to acquire Idenix Pharmaceuticals Inc


Friday, 20 Jun 2014 07:30am EDT 

Merck & Co Inc:Commencing, through subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc.Upon successful closing of tender offer, stockholders of Idenix will receive $24.50 in cash for each share of Idenix common stock validly tendered and not validly withdrawn in offer, without interest and less any required withholding taxes.Following the purchase of shares in tender offer, Idenix will become a wholly-owned subsidiary of Merck.MacKenzie Partners, Inc. is acting as information agent for Merck.Credit Suisse is serving as financial advisor to Merck with this transaction and Hughes Hubbard & Reed LLP as its legal advisor.Merck will file with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer. 

Company Quote

59.38
-0.72 -1.20%
4:03pm EDT